VB 1953

Drug Profile

VB 1953

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Vyome Biosciences
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials
  • Mechanism of Action Bacterial DNA inhibitors; Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acne

Most Recent Events

  • 31 Oct 2016 Phase-I clinical trials in Acne in USA (Topical)
  • 11 Jan 2016 Vyome Biosciences has patent protection for microtechnology gel system (Vyome website, January 2016)
  • 06 Jan 2016 The US FDA accepts Vyome Biosciences' IND application for VB 1953 in Acne
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top